Yoshio Yamaoka

Prof. Yoshio Yamaoka

Department of Medicine-Gastroenterology, Baylor College of Medicine, Houston, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2003 in Science
Verified
Journal Article
Closed access
PDF file
DFDaniel Falush
Daniel Falush
Thierry WirthThierry Wirth
Thierry Wirth
BLBodo Linz
Bodo Linz
JPJonathan K. Pritchard
Jonathan K. Pritchard
MSMatthew Stephens
Matthew Stephens
SSSebastian Suerbaum
Sebastian Suerbaum
Helicobacter pylori , a chronic gastric pathogen of human beings, can be divided into seven populations and subpopulations with distinct geographical distributions. These modern populations derive their gene pools from ancestral populations that arose in Africa, Central Asia, and East Asia. Subsequent spread can be attributed to human migratory fluxes such as the prehistoric colonization of Polynesia and the Americas, the neolithic introduction of farming to Europe, the Bantu expansion within Africa, and the slave trade.

7 February 2007 in Nature
Verified
Journal Article
Closed access
PDF file
BLBodo Linz
Bodo Linz
FBFrançois Balloux
François Balloux
YMYoshan Moodley
Yoshan Moodley
AMAndrea Manica
Andrea Manica
HLHua Liu
Hua Liu
MAMark Achtman
Mark Achtman

12 October 2010 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
Yoshio YamaokaYoshio Yamaoka
Yoshio Yamaoka

19 November 2014 in The European Physical Journal C
Verified
Journal Article
Open access
ABA. J. Bevan
A. J. Bevan
BGB. Golob
B. Golob
TMTh. Mannel
Th. Mannel
SPS. Prell
S. Prell
BYB. D. Yabsley
B. D. Yabsley
DŽD. Žontar
D. Žontar

17 May 2021 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
ETEvariste Tshibangu-Kabamba
Evariste Tshibangu-Kabamba
Yoshio YamaokaYoshio Yamaoka
Yoshio Yamaoka

1 October 2020 in Gut
Verified
Journal Article
Open access
PDF file
JLJyh-Ming Liou
Jyh-Ming Liou
PMPeter Malfertheiner
Peter Malfertheiner
YLYi-Chia Lee
Yi-Chia Lee
BSBor-Shyang Sheu
Bor-Shyang Sheu
KSKentaro Sugano
Kentaro Sugano
Emad El-OmarEmad El-Omar
Emad El-Omar
Objective: A global consensus meeting was held to review current evidence and knowledge gaps and propose collaborative studies on population-wide screening and eradication of Helicobacter pylori for prevention of gastric cancer (GC). Methods: 28 experts from 11 countries reviewed the evidence and modified the statements using the Delphi method, with consensus level predefined as ≥80% of agreement on each statement. The Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach was followed. Results: Consensus was reached in 26 statements. At an individual level, eradication of H. pylori reduces the risk of GC in asymptomatic subjects and is recommended unless there are competing considerations. In cohorts of vulnerable subjects (eg, first-degree relatives of patients with GC), a screen-and-treat strategy is also beneficial. H. pylori eradication in patients with early GC after curative endoscopic resection reduces the risk of metachronous cancer and calls for a re-examination on the hypothesis of ‘the point of no return’. At the general population level, the strategy of screen-and-treat for H. pylori infection is most cost-effective in young adults in regions with a high incidence of GC and is recommended preferably before the development of atrophic gastritis and intestinal metaplasia. However, such a strategy may still be effective in people aged over 50, and may be integrated or included into national healthcare priorities, such as colorectal cancer screening programmes, to optimise the resources. Reliable locally effective regimens based on the principles of antibiotic stewardship are recommended. Subjects at higher risk of GC, such as those with advanced gastric atrophy or intestinal metaplasia, should receive surveillance endoscopy after eradication of H. pylori . Conclusion: Evidence supports the proposal that eradication therapy should be offered to all individuals infected with H. pylori . Vulnerable subjects should be tested, and treated if the test is positive. Mass screening and eradication of H. pylori should be considered in populations at higher risk of GC.